A recently completed clinical trial casts further doubt on teh effectiveness of a procedure used to lower stroke risk in patients with atrial fibrillation, a common heart rhythm disorder affecting millions globally [[1]]. The CLOSURE-AF trial, involving over 300 high-risk patients, found that sealing off the left atrial appendage didn’t significantly improve outcomes compared to standard blood-thinning medication.These findings,presented november 21,2023,add to a growing body of research challenging the role of percutaneous LAA closure as a routine alternative to anticoagulation therapy.
Percutaneous Closure of Left Atrial Appendage Fails to Show Benefit in New Trial
A new clinical trial has found that percutaneous closure of the left atrial appendage (LAA) does not improve outcomes for patients with atrial fibrillation, adding to previous research questioning the procedure’s effectiveness. The findings, released on November 21, 2023, could impact treatment decisions for the millions of people worldwide living with this common heart rhythm disorder.
The trial, known as CLOSURE-AF, involved 302 patients with atrial fibrillation who were considered at high risk for stroke. Participants were randomly assigned to either undergo percutaneous LAA closure with the Amplatzer A2 device or receive standard medical management with anticoagulants. The primary endpoint was a composite of stroke, systemic embolism, or cardiovascular death.
According to the study results, there was no significant difference between the two groups in the primary endpoint. Researchers reported a rate of 5.7% in the LAA closure group compared to 6.2% in the medical management group, a difference that was not statistically significant. There were also no significant differences observed in individual components of the primary endpoint.
“The trial did not demonstrate a benefit of percutaneous LAA closure compared to medical therapy in this population,” researchers stated. “These findings are consistent with previous trials that have failed to show a clear advantage for LAA closure.”
The LAA is a small pouch in the heart where blood can pool and clot, increasing the risk of stroke in patients with atrial fibrillation. Percutaneous LAA closure involves inserting a device to seal off the appendage, theoretically preventing clots from forming and traveling to the brain. While the procedure has gained popularity as an alternative to long-term anticoagulation, its efficacy has remained a subject of debate.
The CLOSURE-AF trial adds to a growing body of evidence suggesting that LAA closure may not be as effective as initially hoped. The findings underscore the importance of carefully considering the risks and benefits of the procedure on an individual patient basis. Further research may be needed to identify specific subgroups of patients who might benefit from LAA closure.
